ACR/ARHP Annual Meeting 2013
Tofacitinib Following Adalimumab Improves Response in Patients with Rheumatoid Arthritis
Changing directly from adalimumab to tofacitinib sustained clinical response and improved ACR response rates in patients with rheumatoid arthritis, an open-label extension study presented at the 2013 ACR/ARHP Annual Meeting has found.